<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807300</url>
  </required_header>
  <id_info>
    <org_study_id>2005-000569-21</org_study_id>
    <nct_id>NCT00807300</nct_id>
  </id_info>
  <brief_title>Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma</brief_title>
  <acronym>CEAL</acronym>
  <official_title>Phase-III-Study to Evaluate the Efficacy of CT-guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Magdeburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous, image-guided tumor ablation has evolved as a genuine alternative for the
      treatment of unresectable hepatocellular carcinoma. Published data exploring stereotactic or
      proton beam percutaneous irradiation have revealed,that hepatocellular carcinoma (HCC) is
      radiosensitive to certain protocols. In Phase I and II studies, the investigators
      investigated the potential role of local irradiation in primary and secondary liver tumors
      employing a Iridium192 source. The promising results of previous studies indicate that
      CT-guided brachytherapy might play a role in the treatment of unresectable HCC.

      Therefore, the investigators started a randomized, controlled, clinical Phase-II study to
      evaluate the efficacy and survival-benefits of brachytherapy versus transarterial
      chemoembolization in patients with unresectable HCC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to untreatable progression</measure>
    <time_frame>the follow up period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>the follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>the follow up period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>brachytherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>transarterial chemoembolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CT-guided brachytherapy</intervention_name>
    <description>catheter placed into the tumor by CT-guidance, radiation with iridium 192</description>
    <arm_group_label>brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transarterial chemoembolization</intervention_name>
    <description>application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery</description>
    <arm_group_label>TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of HCC by histopathology or according to the criteria of the Consensus
             Conference of the European Association for the Study of Liver Disease

          -  unresectable HCC

          -  Karnofsky-Index &gt; 70

          -  estimated life expectancy &gt; 16 weeks

          -  adequate bone marrow function

          -  adequate contraception for female patients

          -  informed consent

        Exclusion Criteria:

          -  portal vein thrombosis on the tumor side

          -  extrahepatic spread

          -  Child C

          -  other untreated malignant disease

          -  general contraindication for chemotherapy

          -  active infectious disease

          -  neuropathy, platin-allergy

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Ricke, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic of Diagnostic Radiology and Nuclear Medicine, University Magdeburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of Diagnostic Radiology and Nuclear Medicine, Medical Faculty, University Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Saxony-anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Magdeburg</investigator_affiliation>
    <investigator_full_name>Jens Ricke</investigator_full_name>
    <investigator_title>Prof. Jens Ricke</investigator_title>
  </responsible_party>
  <keyword>percutaneous treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

